非机器人微创二尖瓣修复:20年单中心经验
该单中心研究纳入2000年2月至2020年3月接受非机器人微创二尖瓣修复的1194例患者,分析长期生存与再手术率。微创修复成功率97%,30天死亡率0.6%,5年、10年、20年生存率分别为96.7%、91.6%、80.0%,再手术率分别为4.4%、10.3%、16.7%。作者认为对退行性二尖瓣反流安全且远期功能结果良好。
要点
- 1194例非机器人微创二尖瓣修复,修复成功率97%,30天死亡率0.6%。
- 5年、10年、20年生存率分别为96.7%、91.6%、80.0%。
- 5年、10年、20年再手术率分别为4.4%、10.3%、16.7%。
核心结论
- 作者认为,对退行性二尖瓣反流行非机器人微创二尖瓣修复是安全的,远期功能结果良好,围术期及晚期死亡率低。
研究设计与样本
- 单中心研究,纳入2000年2月至2020年3月接受非机器人微创二尖瓣修复的全部患者,共1194例,其中17例需行二尖瓣置换。
主要发现
- 患者平均年龄55.1岁(范围47.6至62.7岁),微创修复成功率为97%,30天死亡率为0.6%。
- 5年、10年、20年生存率分别为96.7%(标准差5.8%)、91.6%(标准差1.1%)、80.0%(标准差11.2%)。
- 5年、10年、20年再手术率分别为4.4%(标准差3.2%)、10.3%(标准差7.4%)、16.7%(标准差7.4%)。
- 同期行三尖瓣修复及改良Cryo-maze手术等合并手术者263例。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Minimally invasive mitral valve repair (MVR) promises major advantages over median sternotomy regarding cosmetic results and faster recovery. However, the long-term functional outcome of minimally invasive MVR has been questioned by critics because the limited access may not exclusively promise high-quality repair. This study examines the long-term outcome regarding survival and reoperation rate. METHODS: All patients undergoing minimally invasive MVR from February 2000 until March 2020 were included in this study. Baseline clinical and surgical characteristics were summarized from the internal database. Primary end points were survival and freedom from reoperation, analysed via Kaplan-Meier curves. Secondary end points were periprocedural complications after minimally invasive MVR and incidence for recurrent mitral regurgitation >II°. RESULTS: A total of 1194 patients underwent minimally invasive MVR, in 17 cases mitral valve replacement was required. The mean age was 55.1 years [47.6; 62.7]. The successful minimally invasive repair rate was 97%. The 30-day mortality was 0.6%. Survival was 96.7% [standard deviation (SD): 5.8%], 91.6% (SD: 1.1%) and 80.0% (SD: 11.2%) at 5, 10 and 20 years. The incidence of reoperation was 4.4% (SD: 3.2%), 10.3% (SD: 7.4%) and 16.7% (SD : 7.4%) at 5, 10 and 20 years, respectively. Concomitant procedures such as tricuspid valve repair and modified Cryo-maze procedure were performed in 263 cases. CONCLUSIONS: Minimally invasive MVR for degenerative mitral regurgitation is safe, shows excellent functional long-term results and is associated with low perioperative and late mortality.
引用
- Feirer N, Kornyeva A, Lang M, et al. Non-robotic minimally invasive mitral valve repair: a 20-year single-centre experience. Eur J Cardiothorac Surg. 2022. PMID: 35396837. doi:10.1093/ejcts/ezac223
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。